Lv1
32 积分 2024-03-12 加入
Vertebral formula and congenital abnormalities of the vertebral column in rabbits
5小时前
已完结
SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING
6天前
已完结
Drug Metabolites in Safety Testing
6天前
已完结
Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations
1个月前
已完结
PROTAC targeted protein degraders: the past is prologue
1个月前
已完结
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
1个月前
已完结
Calculating safety margins using total plasma concentration versus unbound plasma concentration - does it make a difference?
2个月前
已完结
Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs
2个月前
已关闭
A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors
2个月前
已关闭
Abstract 6268: TT125-802 is a potent and highly selective CBP/p300 bromodomain inhibitor for the treatment of castration resistant prostate cancer and haematological malignancies
2个月前
已关闭
皖公网安备34019202002308
